Cancer Market Research Reports & Industry Analysis

Cancer is a package of diseases marked by uncurbed growth and proliferation of anomalous cells. The illness is generally assumed to be the fruit of the impact of assorted outside factors and inner forces, such as tobacco smoking, radiation exposure, chemicals’ influences, infectious agents, inherited gene mutations, hormonal disorders, immune system conditions and mutations of other origins, among others.

Thus far, the Cancer Market has already seen noticeable progress in early-stage tumor detection and cure globally. The market for Cancer diagnostics is close to explosive growth, promising to reach approximately EUR 4 billion in value by end-2015. Further, technology discoveries will continue to afford many chances of demystifying the genetic components of the sickness, identifying specific tumor types, and observing biological reaction to cancer treatments. However, the bulk of presently available therapies do not fully protect against some unwelcomed side-effects.

The research reports in this Catalogue present global, regional and nation-level analyses of the Cancer Market development trends over different time spans. The research reports identify major bizopps emerging in the Cancer Market; examine versatile Cancer diagnostic test technologies along with their applications, besides looking into other Cancer Market issues. The research reports also profile the top players and would-be entrants, as well as offer test volume and sales projections.

Publications found: 1,595
Sort by:

2015 Analysis of Cancer Diagnostic Instrumentation, and Strategic Profiles of Leading Suppliers

US$ 2,800.00

This 119-page report reviews current instrumentation technologies, and compares features of major automated and semiautomated analyzers used for cancer diagnostic testing. The report also presents strategic assessments of current and emerging suppliers of ...

January 2015 119 pages

2015 Analysis of Cancer Diagnostic Technologies, and Strategic Profiles of Leading Suppliers

US$ 2,800.00

... assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, ...

January 2015 185 pages

2015 Analysis of Emerging Cancer Diagnostic Tests, and Strategic Profile of Leading Suppliers

US$ 2,800.00

... Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.The report includes an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing ...

January 2015 286 pages

2015 Emerging Point-of-Care Testing Markets: Cancer Clinics, Ambulatory Centers, Surgery Centers, Nursing Homes, Birth Centers

US$ 10,000.00

... POC diagnostic technologies and products, by test. Competitive Assessments - Assessments of major suppliers and emerging market entrants, including their sales, product ... for new POC instruments and reagent systems with potentially significant market appeal during the next ten years.- Design criteria for ...

January 2015 1007 pages

2015 France Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test

US$ 600.00

This report provides an overview of the French cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 25 pages and 7 tables

January 2015 25 pages

2015 Germany Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test

US$ 600.00

This report provides an overview of the German cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 25 pages and 7 tables

January 2015 25 pages

2015 Global Cancer Diagnostic Market: Facilities, Test Volumes, and Sales Forecasts by Country

US$ 1,960.00

This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country. Contains ...

January 2015 11 pages

2015 Italy Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test

US$ 520.00

This report provides an overview of the Italian cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 18 pages and 5 tables

January 2015 18 pages

2015 Japan Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test

US$ 600.00

This report provides an overview of the Japanese cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 23 pages and 6 tables

January 2015 23 pages

2015 Spain Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares

US$ 600.00

This report provides an overview of the Spanish cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 16 pages and 7 tables

January 2015 16 pages

2015 UK Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test

US$ 360.00

This report provides an overview of the U.K. cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 16 pages and 4 tables

January 2015 16 pages

2015 US Cancer Diagnostic Testing Market: Sales Forecasts by Market Segment and Supplier Shares by Test

US$ 680.00

This report provides an overview of the US cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Contains 40 pages and 7 tables

January 2015 40 pages

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

US$ 3,000.00

... Relapsed/ Refractory Multiple Myeloma (RRMM) to further improve survival and quality of life of each patient. Two new drugs have successfully fulfilled this need – POMALYST/ IMNOVID (pomalidomide – POM, Celgene, approved) and Kyprolis (carfilzomib ...

January 2015 82 pages

2015 European Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

US$ 15,760.00

... during the next five years. The report examines trends in major European countries (France, Germany, Italy, Spain, UK); reviews current and emerging ... basis of the disease. During the next five years, the European cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field ...

January 2015 820 pages

2015 Global Cancer Diagnostics Market: Toward a New Future for Tumor Markers R&D Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Country Segment Forecasts, Supplier Shares, Innovative Technologies, Competitive Strategies

US$ 27,800.00

... -tailored to your specific information needs and budget. “2015 Global Cancer Diagnostics Market: Toward a New Future for Tumor Markers R&D Oncogenes, ... Asia; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and ...

January 2015 1200 pages

2015 French Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 5,440.00

'2015 French Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the French cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

January 2015 585 pages

2015 German Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 5,440.00

'2015 German Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the German cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

January 2015 585 pages

2015 Italian Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 5,440.00

2015 Italian Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Italian cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

January 2015 570 pages

2015 Japanese Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 6,080.00

'2015 Japanese Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Japanese cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

January 2015 590 pages

2015 Spanish Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 5,440.00

'2015 Spanish Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Spanish cancer diagnostics markets; reviews current and emerging tests; analyzes potential ...

January 2015 565 pages

2015 UK Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 5,440.00

'2015 UK Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the UK cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of ...

January 2015 565 pages

2015 US Cancer Diagnostics Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

US$ 7,840.00

'2015 US Cancer Diagnostics Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of ...

January 2015 620 pages

2015 Global Cancer Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country

US$ 1,960.00

This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, estimates of the number of laboratories performing cancer tests, as well as ten-year test volume and sales forecasts by country. Contains ...

January 2015 11 pages

2015 Emerging Cancer Diagnostic Tests and Companies Developing New Technologies

US$ 2,280.00

... Factors, Lymphokines, Immunohistochemical Stains and others. The report presents an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing or ...

January 2015 260 pages

2015 World Cancer Diagnostics Market Key Players: Strategic Assessments of Major Suppliers and Emerging Market Entrants

US$ 2,000.00

This report presents strategic analyses of major current and emerging suppliers of cancer diagnostic products in terms of their sales, market shares, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Contains 80 pages

January 2015 80 pages

Dendritic Cell Cancer Vaccine Market & Clinical Insight

US$ 1,800.00

... Dendritic Cell Cancer Vaccines Dendritic Cell Vaccine Market Overview Market Dynamics (Drivers, Challenges & Future Prospects) Clinical Pipeline Insight by Phase, Indication & Company Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 Majority of Dendritic Cell Cancer Vaccine ...

January 2015 190 pages

Global Non Small Cell Lung Cancer Market & Pipeline Insight

US$ 2,400.00

... Non Small Cell Lung Cancer Market & Pipeline Insight” Report Highlights: NSCLC Therapy Market Overview Mechanism of NSCLC Therapeutics NSCLC Therapy Market Dynamics: Drivers, Challenges & Future Prospects) NSCLC Drug Pipeline ...

January 2015 750 pages

Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015

US$ 1,500.00

... body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body ... ” Report Highlights: Introduction to Prostate Cancer Vaccine Mechanism of Prostate Cancer Vaccine Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country ...

January 2015 155 pages

Small Molecule Cancer Drug Clinical Pipeline Insight

US$ 2,400.00

... the treatment of Non-Small Cell Lung Cancer (NSCLC), Colon cancer, Breast and other cancers. Development of small molecule cancer drug generally ... Insight” Report Findings: Role of Small Molecule Drug in Cancer Treatment Mechanism of Small Molecule Cancer Drug Small Molecule Cancer Drugs Market Dynamics ...

January 2015 1650 pages

Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies

US$ 3,900.00

... is vital for ensuring optimal performance levels of Medical Affairs teams. In Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and ... and timely EdgeMap and Need-Gap analysis of oncologists' perceptions of Medical Affairs teams highlighting good and bad performance and identifying ...

December 2014 -

Competitor Analysis: Cancer Peptides

US$ 500.00

Competitor Analysis: Cancer Peptides The Competitive Intelligence Report Cancer Peptides as of November 2014 provides a competitor analysis in the product portfolios and development pipeline of peptide therapeutics for treatment of cancer. Purchase of the pdf report includes a 6-month online access to the ...

November 2014 99 pages

Physician Views: Reaction to Bristol-Myers Squibb's Opdivo data in non-small-cell lung cancer

US$ 695.00

... , were unveiled (ViewPoints: Investors respond in kind to impressive data for Bristol-Myers Squibb NSCLC immunotherapy). Checkmate-063 recruited 117 patients, each ... , noting that a 21 percent rate (or 18 percent for squamous patients) cited by Bristol-Myers Squibb stemmed from a database comprising only Medicare patients aged ...

November 2014 -

Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

US$ 2,400.00

... Non Hodgkin Lymphoma therapeutics. “Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight: Global Non Hodgkin Lymphoma Market Overview Mechanism of Non Hodgkin Lymphoma Therapeutics Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company Global Non Hodgkin Lymphoma Pipeline ...

November 2014 573 pages

Global Cancer Monoclonal Antibodies Market & Pipeline Insight

US$ 2,400.00

... Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country Cancer Monoclonal Antibodies in Pipeline: 605 Majority Cancer Monoclonal Antibodies Preclinical Phase: 258 Marketed Cancer Monoclonal Antibodies: 34 Cancer Monoclonal Antibodies ...

October 2014 1400 pages

Global Cancer Kinase Inhibitors Market & Pipeline Insight

US$ 2,400.00

... Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight: Classification & Mechanism of Kinase Inhibitors Cancer Kinase Inhibitors Therapy Market Overview Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country Marketed Cancer Kinase Inhibitors Therapy ...

October 2014 1500 pages

Global Breast Cancer Vaccine Clinical Trial Insight

US$ 1,200.00

... Breast Cancer Vaccine Clinical Trial Insight” Report Highlight: Global Breast Cancer Vaccine Market Overview Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines Detailed Clinical Insight on Breast Cancer Vaccine Pipeline ...

October 2014 134 pages

Physician Views: The PD-1 inhibitor class lands – how do US oncologists expect to initially use Merck & Co.'s Keytruda?

US$ 695.00

... Yervoy (ipilimumab) and, if BRAF V600-mutation positive, a BRAF inhibitor (see also Physician Views Poll Results – Oncologists suggest Mekinist/Tafinlar combination will ... approval – the PD-1/PD-L1 inhibitors are expected to spearhead evolution of a multi-billion dollar market over the next decade – this Physician Views poll contains a second ...

September 2014 -

Global Cancer Vaccines Market & Pipeline Analysis

US$ 2,400.00

... Cancer Vaccines Delivery Cancer Vaccines: Mechanism & Innovations Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country Global Cancer Vaccine Clinical Pipeline: 289 Vaccines Marketed Cancer Vaccines: 12 Vaccines Regulatory Framework for Cancer Vaccines Development & Marketing ...

September 2014 864 pages

Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape?

US$ 695.00

... 4/6 inhibitor class. Expectations for palbociclib were flying high in 2012 when Pfizer reported preliminary results from the Phase II PALOMA-1 trial showing the drug improved progression-free survival (PFS) by 18.6 months when added to Femara in postmenopausal women with oestrogen receptor (ER) positive, HER2 ...

August 2014 -

Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014

US$ 2,000.00

... trials studies have demonstrated the fact that the potential of peptide based drugs to prevent and eradicate cancer is far effective than conventional ... therapy, both conventional and peptide based cancer therapeutics are used for the treatment. “Global Peptide Cancer Therapeutics Market & Pipeline Insight ...

August 2014 556 pages

Global Cancer Generics Market Outlook 2018

US$ 1,400.00

... growth. According to our latest research report “Global Cancer Generics Market Outlook 2018”, the global oncology market touched a mark of US$ 91 Billion in 2013 ... future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the ...

July 2014 100 pages

Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies

US$ 3,900.00

... maintaining front line, product level access and education. In Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies, FirstWord ... marketed and four pipeline products Examination of physicians’ current usage of Medical Affairs teams services Key findings regarding the most and ...

July 2014 54 pages

2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

US$ 27,600.00

... is available by country, section, market segment, and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Global Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, ...

July 2014 1200 pages

2014 Market Segmentation Analysis of the European Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations

US$ 15,760.00

... is available by country, section, market segment, and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the European Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, ...

July 2014 820 pages

2014 Market Segmentation Analysis of the French Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals and Commercial Labs

US$ 5,360.00

... and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the French Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. French Market Overview Five-year test volume and sales ...

July 2014 585 pages

2014 Market Segmentation Analysis of the German Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs and Physician Offices

US$ 5,360.00

... and can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the German Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. German Market Overview Five-year test volume and sales ...

July 2014 585 pages

2014 Market Segmentation Analysis of the Italian Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals and Commercial Labs

US$ 5,360.00

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Italian Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Italian Market Overview Five-year test volume and sales ...

July 2014 570 pages

2014 Market Segmentation Analysis of the Japanese Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals and Commercial Labs

US$ 7,040.00

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Japanese Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Japanese Market Overview Five-year test volume and sales ...

July 2014 590 pages

2014 Market Segmentation Analysis of the Spanish Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals and Commercial Labs

US$ 5,360.00

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Spanish Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Spanish Market Overview Five-year test volume and sales ...

July 2014 565 pages

2014 Market Segmentation Analysis of the UK Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals and Commercial Labs

US$ 5,360.00

... can be custom-tailored to your specific information needs and budget. 2014 Market Segmentation Analysis of the Spanish Cancer Diagnostics Industry: Oncogenes, Biochemical ... the growing demand for malignancy assays and the rapid market expansion. Spanish Market Overview Five-year test volume and sales ...

July 2014 565 pages

Filters

Search

Publishers

20
3
4
1
1
4
1
24
2
2
27
10
1
15
1
6
9
10
4
10
31
5
3
7
1
8
3
1
3
12
5
1
4
12
25
5
11
43
8
1,108
6
74
17
10
12
5
1
10
9

Regions

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
4
5
1
5
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
15
10
10
7
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
8
8
7
58
54
54
54
53
52
53
74
672

Price

Date

Pages

Offers

1